Abstract: In some implementations, a device may receive training data identifying a set of workflows. The device may generate a set of workflow templates based on the training data identifying the set of workflows, wherein a workflow template, of the set of workflow templates, is associated with a set of steps for completing a task associated with the workflow template. The device may receive, from a client device associated with an entity, a new task for automation using a new workflow. The device may parse the new task to identify one or more steps associated with the new task. The device may identify one or more workflow templates. The device may a workflow recommendation relating to the one or more workflow templates. The device may output workflow data associated with the workflow recommendation.

Abstract: Techniques to eliminate duplicate packets from a stream of packets. A method includes receiving a packet, hashing elements of the packet to obtain a packet partial signature, generating an action data value by appending, to the packet partial signature, unhashed packet information, accessing a hash store location in a hash store based on the action data value, determining, based on data stored at the hash store location, whether the packet is a duplicate of a previously-received packet, and based on whether the packet is a duplicate of a previously-received packet, one of allowing and preventing one of the packet and a copy of the packet to reach a downstream network node.

Abstract: The present disclosure is directed to methods of preparing genetically engineered lymphocytes. In addition, methods of using the genetically engineered lymphocytes in T cell therapy for cancers are also disclosed.

Abstract: The present disclosure relates to the field of cell therapy, and more specifically, to improving CAR and/or TCR function through improvement of improvement of cytokine signaling.

Abstract: Immune cell engineered to inhibit the endogenous expression of one or more of Blimp-1 and A20 and/or overexpress one or more of exogenous TCF7 and Bach2. Method of treating cancer, comprising administering the cells described herein. Method of increasing one or more of a peak fold proliferation rate, a killing efficiency, or inducing the cellular characteristics associated with naïve phenotype of an immune cell, comprising introducing an exogenous construct encoding a CAR or a TCR, and inhibiting the endogenous expression of one or more of Blimp-1 and A20, and/or introducing an exogenous construct encoding one or more of TCF7 and Bach2. Method of generating a modified immune cell, comprising introducing an exogenous construct encoding a CAR or a TCR, and inhibiting the endogenous expression of one or more of Blimp-1 and A20, and/or introducing an exogenous construct encoding one or more of TCF7 and B ach2.